MEDIA ADVISORY: NCI reports significant clinical findings for treatment of breast cancer: Trastuzumab combined with chemotherapy improves disease-free survival

Monday, April 25, 2005

What
Results from two large randomized clinical trials for patients with HER-2 positive invasive breast cancer show that patients who received trastuzumab (Herceptin®) in combination with chemotherapy had a significant decrease in risk for breast cancer recurrence compared with patients who received the same chemotherapy without trastuzumab.

"These findings are dramatic," says internationally known Mayo Clinic medical oncologist Edith A. Perez, M.D., who chaired the North Central Cancer Treatment Group (NCCTG) trial. "These data confirm that we now have a very potent weapon against the recurrence of cancer cells that overexpress HER-2, which tend to grow fast and are generally more likely to recur."

Learn more about this breakthrough for breast cancer.

Read the news release from the National Cancer Institute (NCI).

Who
Edith Perez, M.D., a Mayo Clinic medical oncologist who chaired the NCCTG trial N9831, will be available for interviews. Contact Erik Kaldor at (904) 953-2299 for further information.

Media Contact
Erik Kaldor
Mayo Clinic Jacksonville
(904) 953-2299

###

To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com is available as a resource for your health stories.